Conversion Therapy for Advanced Hepatocellular Carcinoma Following Complete Response to Transarterial Radioembolization Combined with Atezolizumab and Bevacizumab. Radiology and Oncology, v. 60, n. 1, p. 40–48, 26 Mar.2026.